Reply: Neurofascin as target of autoantibodies in Guillain-Barre syndrome

Abstract

Sir, The letter by Pruss and colleagues on the detection antibodies to neurofascin in Guillain–Barre syndrome raises a number of important questions and highlights exciting recent developments in the field of novel autoantibodies in both peripheral and central nervous system disorders. As such, there is a compelling case for investigating this area in much more detail. Neurofascin is one of a large number of potential nodal complex protein candidates to be explored, as Pruss et al . point out. While in principle this sounds straightforward, in practice it is complicated in terms of technical issues …